Evommune Updates Corporate Presentation and Reports Phase 2a Efficacy for EVO301

Evommune, Inc. filed a Current Report on Form 8-K with the Securities and Exchange Commission on September 15, 2026, announcing the posting of an updated corporate presentation. The filing states that the presentation was uploaded to the “Company Info” page of the company’s website on that date. A copy of the presentation is included as Exhibit 99.1 to the filing.

The presentation details the company’s pipeline of product candidates, including EVO301, EVO756, and EVO646. EVO301 is described as a long-acting IL-18 binding protein fusion therapeutic designed to neutralize IL-18 signaling. The company states that EVO301 has the potential to become a foundational therapy in atopic dermatitis and other IL-18 driven diseases.

Regarding clinical data, the presentation highlights the results of a Phase 2a proof-of-concept trial for EVO301 in adults with moderate-to-severe atopic dermatitis. The trial, identified by NCT06723405, randomized 70 patients in a double-blind, placebo-controlled design. The primary endpoint was the percent change from baseline in the Eczema Area and Severity Index (EASI) at week 12.

The filing reports that the trial achieved its primary endpoint. Placebo-adjusted EASI improvement was 34% at week 8 and 33% at week 12. Additionally, 23% of patients achieved an Investigator Global Assessment (IGA) score of 0/1 at week 12, compared to 0% in the placebo group. The presentation notes that the trial demonstrated statistically significant EASI reductions at weeks 4, 8, and 12, with no treatment-related serious or severe adverse events reported.

The presentation also outlines the company’s financial position, stating that Evommune has approximately $287 million in cash and investments. The company anticipates this runway will extend into 2029.

Regarding future milestones, the presentation indicates that Evommune plans to initiate a Phase 2b trial for EVO301 in atopic dermatitis with a subcutaneous formulation in mid-2027. For EVO756, the company expects top-line data from a Phase 2b migraine trial in 2027. Finally, the presentation states that EVO646 is planned to enter clinical trials in the first half of 2027.